COMP <GO>
BIIB vs RVMD // ENTERPRISE SCALE & MARKET CAP
Biogen Inc. (NASDAQ) VS. Revolution Medicines Inc. (NASDAQ) • 15-METRIC TALLY: BIIB 6
— RVMD 3
▲ ENTERPRISE SCALE & MARKET CAP LEADER: RVMD
LAST: $249.65 (+2.30%) • MKT CAP: $36.90B
market-cap
$36.90B
LAST: $190.27 (+0.82%) • MKT CAP: $40.78B
market-cap
$40.78B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BIIB VS. RVMD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BIIB | RVMD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 75.70% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.40% | -28.60% | +35.00 | BIIB | /roic <GO> |
| EV/EBITDA & P/E Valuation | 22.3x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 5.56% | -2.24% | +7.80 | BIIB | /fcf-yield <GO> |
| Operating Margin | 15.90% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 13.10% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 2.20% | 15.40% | -13.20 | RVMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.70 | 26.00 | -22.30 | RVMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 5/9 | +2.00 | BIIB | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.8 | 47.8 | +14.00 | BIIB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 1.07 | +0.03 | BIIB | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.5x | 34.0x | -7.50 | BIIB | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $36.90B | $40.78B | -$3.88B | RVMD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BIIB REV | RVMD REV | BIIB GROSS % | RVMD GROSS % | BIIB FCF | RVMD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $9.89B | $0 | 75.7% | — | $2.05B | -$913.7M |
| FY 2024 | $9.68B | $0 | 76.1% | — | $2.72B | -$567.7M |
| FY 2023 | $9.84B | $11.6M | — | — | $1.10B | -$351.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BIIB // BETA 1.10
RVMD // BETA 1.07